Last reviewed · How we verify
pbi-shRNA STMN1 LP — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
pbi-shRNA STMN1 LP (pbi-shRNA STMN1 LP) — Gradalis, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pbi-shRNA STMN1 LP TARGET | pbi-shRNA STMN1 LP | Gradalis, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pbi-shRNA STMN1 LP CI watch — RSS
- pbi-shRNA STMN1 LP CI watch — Atom
- pbi-shRNA STMN1 LP CI watch — JSON
- pbi-shRNA STMN1 LP alone — RSS
Cite this brief
Drug Landscape (2026). pbi-shRNA STMN1 LP — Competitive Intelligence Brief. https://druglandscape.com/ci/pbi-shrna-stmn1-lp. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab